We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Profile Thera. | PTP | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | - |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| Top Posts |
|---|
Posted at 01/7/2004 07:18 by maywillow RNS Number:3464ARespironics, Inc. 1 July 2004 Not for release, publication or distribution, in whole or in part, in, into or from the United States, Canada, Australia or Japan. Embargoed until 7:00 a.m. on 1 July 2004 Recommended Cash Offer by Respironics UK Holding Company Limited ("Respironics UK") for Profile Therapeutics plc ("Profile") Offer declared unconditional in all respects The board of Respironics UK announces that the recommended cash offer (the " Offer") made by Bridgewell Limited on behalf of Respironics UK for the entire issued and to be issued share capital of Profile as set out in the Offer document dated 21 May 2004 (the "Offer Document") has been declared unconditional in all respects and the remaining conditions have been satisfied or waived. The Offer will remain open until further notice. Profile Shareholders who have not yet accepted the Offer are encouraged to complete and return the Form of Acceptance as soon as possible so as to be received either by post or by hand by Capita IRG Plc, Corporate Actions, PO Box 166, The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TH. Respironics UK intends to implement the procedures set out in Sections 428 to 430F (inclusive) of the Companies Act 1985 to acquire compulsorily any outstanding Profile Shares to which the Offer relates. Respironics UK also intends, subject to any applicable requirements of the UK Listing Authority, to procure that Profile applies to the London Stock Exchange for the admission to trading of the Profile Shares to be cancelled. Such cancellation will take effect no earlier than 20 business days from the date of this announcement and is expected to significantly reduce the liquidity and marketability of any Profile Shares not assented to the Offer. By 3:00 pm on 30 June 2004, valid acceptances had been received in respect of a total of 48,353,256 Profile Shares, representing approximately 98.39 per cent. of the existing issued share capital of Profile. During the Offer Period Respironics UK obtained irrevocable undertakings to accept the Offer from certain Profile Shareholders (including the Directors of Profile) in respect of 30,587,783 Profile Shares representing in aggregate approximately 62.2 per cent. of the existing issued share capital of Profile. Respironics UK has received valid acceptances in respect of all Profile Shares to which these undertakings related. Neither Respironics UK, nor any person acting, or deemed to be acting, in concert with Respironics UK for the purpose of the Offer owned, or controlled, any Profile Shares or any rights over any Profile Shares immediately prior to the commencement of the Offer Period. Save as disclosed in this announcement, neither Respironics UK nor any person acting, or deemed to be acting, in concert with Respironics UK has acquired or agreed to acquire Profile Shares (or rights over Profile Shares) during the Offer Period. Unless the context otherwise requires, defined terms used in this announcement shall have the same meanings given to them in the Offer Document. Enquiries: Respironics, Inc. Dan Bevevino (Vice President and CFO) +1 724 387 5235 Maryellen Bizzack (Director, Marketing & Communications) +1 724 387 5006 Bridgewell Limited John Craven (Director) 020 7003 3108 Profile Therapeutics plc John Lisle (Chief Executive Officer) 0870 770 2004 PricewaterhouseCoope Darren Bryant (Director) 020 7804 4089 Bridgewell, which is regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for Respironics, Inc. and Respironics UK and no one else in connection with the Offer and will not be responsible to anyone other than Respironics, Inc. and Respironics UK for providing the protections afforded to its customers or for providing advice in relation to the Offer or in relation to the contents of this announcement or any transaction or arrangement referred to herein. PricewaterhouseCoope Kingdom by the Financial Services Authority for designated investment business, is acting exclusively for Profile and for no one else in relation to the Offer and will not be responsible to anyone other than Profile for providing the protections afforded to clients of PricewaterhouseCoope advice in relation to the Offer or any other matter referred to in this announcement. This announcement does not constitute an offer to sell or an invitation to purchase or subscribe for any securities or the solicitation of an offer to buy or subscribe for any securities pursuant to the Offer or otherwise. The Offer is being made solely by the Offer Document and the Form of Acceptance accompanying the Offer Document, which contain the full terms and conditions of the Offer, including details of how the Offer may be accepted. The laws of relevant jurisdictions may affect the availability of the Offer to persons not resident in the United Kingdom. Persons who are not resident in the United Kingdom, or who are subject to the laws of any jurisdiction other than the United Kingdom, should inform themselves about, and observe, any applicable legal and regulatory requirements. The Offer is not being made, directly or indirectly, in or into the United States or by use of the mails of, or by any means or instrumentality (including, without limitation, facsimile or other electronic transmission, telex or telephone) of inter-state or foreign commerce of, or any facility of, a national, state or other securities exchange of, the United States, nor is it being made directly or indirectly in or into Canada, Australia or Japan and the Offer cannot be accepted by any such use, means, instrumentality or facility or from within the United States, Canada, Australia or Japan or any other such jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction. Accordingly, copies of this press announcement, the Offer Document and the Form of Acceptance are not being, will not be and must not be mailed or otherwise forwarded, distributed or sent in, into or from the United States, Canada, Australia or Japan or any other such jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction and persons receiving this press announcement, the Offer Document and Form of Acceptance (including without limitation custodians, nominees and trustees) must not mail, forward, distribute or send them in, into or from the United States, Canada, Australia or Japan or any other such jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction. This information is provided by RNS The company news service from the London Stock Exchange END OUPBRGDLIDXGGSG Profile Thera.(PTP) |
Posted at 19/2/2004 16:13 by kombimatec More good news from PTP and they will continue to rise as they are exceeding their targets on sales and cashflow. The company is unusual in the pharma sector because it has an actual product. |
Posted at 08/1/2004 08:02 by zapa Agreed, one question though re M.L. Labs and their handheld.Is it in compatition with PTP? |
Posted at 10/6/2002 17:01 by jaygar I asked PTP the above and got this e mail :Thank you for your query. The answer is that I cannot give you a definitive date partly because the MCA has a huge backlog of generic licence applications to get through. We filed on 14th March 2002. Technically the MCA has a period of 6 months to review the file; we believe that the current workload is increasing this time frame to between 6 and 12 months. This means that we should anticipate an approval (subject to any questions the MCA may have for us) anytime between September 2002 and March/April 2003 although clearly it could be longer if the backlog is greater than our sources believe. |
Posted at 29/5/2002 22:54 by jaygar Am I the only person holding PTP ?? :) |
Posted at 18/5/2002 11:36 by jaygar Seems awfully quiet on PTP. I see Britannic Investments have increased their holding....any news anywhere ? |
Posted at 21/3/2002 18:28 by jc111 Totally undervalued imo.I Read the Seymour Pierce Research Report and bought more. Entitled "Buy now, get two divisions free" 14th march 2002. A snippet from the report: - "Two divisions in for free??? Looking on a fundamental basis the sum of parts valuation of £11.1m of cash and the Medic-Aid valued at 2-2.5 times half year sales (the division turned over £5.8m) the company should be trading at a range of 44-52p. Based on our full year forecast Medic-Aid sales of £12.2m a price of 72-85p per share would appear feasible. This is at a premium to the current price in effect offering two divisions with significant growth potential "for free". Also Profile on the 14th of March announced they had submitted an application to the UK Medicines Control Agency for Marketing Authorisation for PromixinTM. Could bring in some big revenues when launched onto the market. 'Promixin is Profile's branded generic antibiotic that is administered by inhalation to treat the chronic lung infections associated with cystic fibrosis.' Simon Shaw, Profile's Chief Operating Officer, said: 'Submission of our first drug application is an important milestone for Profile and, subject to the regulatory approval process, we look forward to making Promixin available for the treatment of this severe disease as soon as possible.' """"""Cystic fibrosis is the most common terminal genetic condition amongst Caucasians, with some 60,000 patients in the US and Europe. Death from cystic fibrosis is due mainly to pulmonary complications. The condition is commonly treated with inhaled medications that aim to minimise infection of the lung. It is estimated that the potential world market for antibiotics in the treatment of cystic fibrosis is in the region of $200-300 million per annum."""""" The stock market hasn't priced this in at all. PTP has a market value of £24m. No wonder 3i have bought in and noticed some big trades last few days. DYOR JC |
Posted at 05/12/2001 22:28 by adrenalin.dog Try this link for some info on PTP |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
